{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T05:33:10Z","timestamp":1760851990273,"version":"3.29.0"},"reference-count":41,"publisher":"Elsevier BV","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mol Pharmacol"],"published-print":{"date-parts":[[2002,3,1]]},"DOI":"10.1124\/mol.61.3.620","type":"journal-article","created":{"date-parts":[[2003,1,15]],"date-time":"2003-01-15T23:12:39Z","timestamp":1042672359000},"page":"620-627","source":"Crossref","is-referenced-by-count":11,"title":["Vesnarinone Causes Oxidative Damage by Inhibiting Catalase Function through Ceramide Action in Myeloid Cell Apoptosis"],"prefix":"10.1016","volume":"61","author":[{"given":"Tadakazu","family":"Kondo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiko","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiyuki","family":"Kitano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuya","family":"Iwai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsumasa","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hisanori","family":"Umehara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoharu","family":"Daido","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naochika","family":"Domae","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaro","family":"Tashima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Uchiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiro","family":"Okazaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","published-online":{"date-parts":[[2002,3,1]]},"reference":[{"key":"2019081414074766000_61.3.620.1","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1159\/000203608","article-title":"Possible involvement of bone marrow stromal cells in agranulocytosis caused by vesnarinone treatment.","volume":"98","author":"Aizawa","year":"1997","journal-title":"Acta Haematol"},{"key":"2019081414074766000_61.3.620.2","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.4049\/jimmunol.130.4.1910","article-title":"Flow cytometric studies of oxidative product formation by neutrophils: a graded response to membrane stimulation.","volume":"130","author":"Bass","year":"1983","journal-title":"J Immunol"},{"key":"2019081414074766000_61.3.620.3","doi-asserted-by":"publisher","DOI":"10.1016\/0014-5793(96)00942-8"},{"key":"2019081414074766000_61.3.620.4","doi-asserted-by":"publisher","DOI":"10.1016\/1071-9164(95)90030-6"},{"key":"2019081414074766000_61.3.620.5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199812173392503"},{"key":"2019081414074766000_61.3.620.6","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-5793(98)00688-7"},{"key":"2019081414074766000_61.3.620.7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199307153290301"},{"key":"2019081414074766000_61.3.620.8","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.93.3.474"},{"key":"2019081414074766000_61.3.620.9","first-page":"1180","article-title":"Vesnarinone exhibits antitumor effect against myeloid leukemia cells via apoptosis.","volume":"25","author":"Fujiwara","year":"1997","journal-title":"Exp Hematol"},{"key":"2019081414074766000_61.3.620.10","doi-asserted-by":"publisher","DOI":"10.1126\/science.274.5294.1855"},{"key":"2019081414074766000_61.3.620.11","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.990130704"},{"key":"2019081414074766000_61.3.620.12","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-5728(99)00037-5"},{"key":"2019081414074766000_61.3.620.13","first-page":"165b","article-title":"Induction of apoptosis by modulation of ceramide metabolism in multi-drug resistant human leukemia cell lines (Abstract).","volume":"92","author":"Kitano","year":"1998","journal-title":"Blood"},{"key":"2019081414074766000_61.3.620.14","first-page":"41","article-title":"Antitumor effect of vesnarinone on human hepatocellular carcinoma cell lines.","volume":"14","author":"Kubo","year":"1999","journal-title":"Int J Oncol"},{"key":"2019081414074766000_61.3.620.15","first-page":"291","article-title":"HL-60 cells isolated for resistance to vincristine are defective in 12-O-tetradecanoylphorbol-13-acetate induced differentiation and the formation of a functional AP-1 complex.","volume":"4","author":"Ma","year":"1992","journal-title":"Oncol Res"},{"key":"2019081414074766000_61.3.620.16","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.164.11.5815"},{"key":"2019081414074766000_61.3.620.17","doi-asserted-by":"publisher","DOI":"10.1016\/S0300-483X(00)00306-1"},{"key":"2019081414074766000_61.3.620.18","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/16.suppl_O.140"},{"key":"2019081414074766000_61.3.620.19","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/BF03344959","article-title":"Antithyroid drug-induced agranulocytosis: clinical experience with ten patients treated at one institution and review of the literature.","volume":"17","author":"Meyer-Gessner","year":"1994","journal-title":"J Endocrinol Invest"},{"key":"2019081414074766000_61.3.620.20","first-page":"509","article-title":"Effects of vesnarinone on the bone marrow stromal cell-dependent proliferation and differentiation of HL60 cells in vitro.","volume":"25","author":"Nabeshima","year":"1997","journal-title":"Exp Hematol"},{"key":"2019081414074766000_61.3.620.21","doi-asserted-by":"publisher","DOI":"10.1097\/00001813-199708000-00007"},{"key":"2019081414074766000_61.3.620.22","doi-asserted-by":"crossref","first-page":"19076","DOI":"10.1016\/S0021-9258(19)47268-2","article-title":"Sphingomyelin turnover induced by vitamin D3 in HL-60 cells. Role in cell differentiation.","volume":"264","author":"Okazaki","year":"1989","journal-title":"J Biol Chem"},{"key":"2019081414074766000_61.3.620.23","doi-asserted-by":"crossref","first-page":"15823","DOI":"10.1016\/S0021-9258(18)55472-7","article-title":"Role of ceramide as a lipid mediator of 1 alpha,25-dihydroxyvitamin D3-induced HL-60 cell differentiation.","volume":"265","author":"Okazaki","year":"1990","journal-title":"J Biol Chem"},{"key":"2019081414074766000_61.3.620.24","doi-asserted-by":"publisher","DOI":"10.1016\/S0898-6568(98)00035-7"},{"key":"2019081414074766000_61.3.620.25","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1182\/blood.V87.6.2361.bloodjournal8762361","article-title":"Inhibition of CD4 cross-linking induced lymphocytes apoptosis by vesnarinone as a novel immunomodulating agent: vesnarinone inhibits Fas expression and apoptosis by blocking cytokine secretion.","volume":"87","author":"Oyaizu","year":"1996","journal-title":"Blood"},{"key":"2019081414074766000_61.3.620.26","doi-asserted-by":"crossref","first-page":"3974","DOI":"10.1200\/JCO.2000.18.23.3974","article-title":"Phase I and pharmacokinetic study of the differentiating agent vesnarinone in combination with gemcitabine in patients with advanced cancer.","volume":"18","author":"Patnaik","year":"2000","journal-title":"J Clin Oncol"},{"key":"2019081414074766000_61.3.620.27","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.272.34.21388"},{"key":"2019081414074766000_61.3.620.28","doi-asserted-by":"publisher","DOI":"10.1016\/S0891-5849(99)00137-9"},{"key":"2019081414074766000_61.3.620.29","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.274.40.28161"},{"key":"2019081414074766000_61.3.620.30","doi-asserted-by":"publisher","DOI":"10.1016\/0753-3322(96)84825-6"},{"key":"2019081414074766000_61.3.620.31","doi-asserted-by":"publisher","DOI":"10.1016\/S1071-9164(96)80048-0"},{"key":"2019081414074766000_61.3.620.32","first-page":"37","article-title":"Induction of differentiation and enhancement of vincristine sensitivity of human erythroleukemia HEL cells by vesnarinone, a positive inotropic agent.","volume":"24","author":"Sato","year":"1996","journal-title":"Exp Hematol"},{"key":"2019081414074766000_61.3.620.33","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-2828(95)91695-4"},{"key":"2019081414074766000_61.3.620.34","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1002\/j.1460-2075.1993.tb05978.x","article-title":"Depletion of the mitochondrial electron transport abrogates the cytotoxic and gene-inductive effects of TNF.","volume":"12","author":"Schulze-Osthoff","year":"1993","journal-title":"EMBO (Eur Mol Biol Organ) J"},{"key":"2019081414074766000_61.3.620.35","doi-asserted-by":"crossref","first-page":"L11","DOI":"10.1016\/0024-3205(94)00580-X","article-title":"Inhibition of cytokine production by a new inotropic agent, vesnarinone, in human lymphocytes, T cell line: and monocytic cell line.","volume":"54","author":"Shioi","year":"1994","journal-title":"Life Sci"},{"key":"2019081414074766000_61.3.620.36","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-5793(00)01422-8"},{"key":"2019081414074766000_61.3.620.37","doi-asserted-by":"publisher","DOI":"10.1159\/000017408"},{"key":"2019081414074766000_61.3.620.38","first-page":"865","article-title":"Metabolism of vesnarinone by activated neutrophils: implications for vesnarinone-induced agranulocytosis.","volume":"270","author":"Uetrecht","year":"1994","journal-title":"J Pharmacol Exp Ther"},{"key":"2019081414074766000_61.3.620.39","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(89)90944-6"},{"key":"2019081414074766000_61.3.620.40","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-3835(99)00061-0"},{"key":"2019081414074766000_61.3.620.41","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-3835(98)00187-6"}],"container-title":["Molecular Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/mol.61.3.620","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T18:34:00Z","timestamp":1732732440000},"score":1,"resource":{"primary":{"URL":"http:\/\/molpharm.aspetjournals.org\/lookup\/doi\/10.1124\/mol.61.3.620"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,3,1]]},"references-count":41,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2002,3,1]]},"published-print":{"date-parts":[[2002,3,1]]}},"alternative-id":["10.1124\/mol.61.3.620"],"URL":"https:\/\/doi.org\/10.1124\/mol.61.3.620","relation":{},"ISSN":["0026-895X","1521-0111"],"issn-type":[{"type":"print","value":"0026-895X"},{"type":"electronic","value":"1521-0111"}],"subject":[],"published":{"date-parts":[[2002,3,1]]}}}